Brevan Howard Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Brevan Howard Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$332K	Buy	30,654 +10,945	+56%	+$99.2K	﹤0.01%	1652
2026 Q1	$250K	Sell	19,709 -69,823	-78%	-$793K	﹤0.01%	1759
2025 Q4	$732K	Buy	89,532 +40,437	+82%	+$465K	0.01%	912
2025 Q3	$589K	Buy	49,095 +14,370	+41%	+$151K	﹤0.01%	1198
2025 Q2	$352K	Buy	+34,725	New	+$233K	﹤0.01%	1493

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brevan Howard Capital Management's ORIC Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Oric Pharmaceuticals (ORIC) stake by 56% in Q2 2026, buying an estimated $99.2K and bringing the position to 30,654 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

Brevan Howard Capital Management first reported a position in ORIC in Q2 2025 and has held it in 5 quarters since. The position peaked at $732K in Q4 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Brevan Howard Capital Management held 30,654 shares of Oric Pharmaceuticals worth $332K as of Q2 2026.
Brevan Howard Capital Management bought 10,945 Oric Pharmaceuticals shares in Q2 2026, an estimated $99.2K.
Oric Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1652 holding.
Brevan Howard Capital Management first reported a position in Oric Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
Brevan Howard Capital Management's Oric Pharmaceuticals position peaked at $732K in Q4 2025.
180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.